The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide

• Published in: BMC cancer Vol. 22; no. 1; p. 375
• Main Authors: Poteska, Renata, Rahbar, Kambiz, Semjonow, Axel, Schrader, Andres Jan, Boegemann, Martin, Schlack, Katrin
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.04.2022; BioMed Central; BMC
• Subjects: Alkaline phosphatase; Androgens; Biomarkers; bmCRPC; Bone cancer; Bones; Cancer therapies; Castration; Chemotherapy; Dehydrogenases; Drug therapy; Enzalutamide; Health aspects; Lactate dehydrogenase; Lactic acid; Magnetic resonance imaging; Medical prognosis; Metastases; Metastasis; Multivariate analysis; Patients; Phosphatase; Prognosis; Prostate cancer; Prostate specific antigen; Regression analysis; Scintigraphy; Statistical analysis; Survival; Germany; Prostate specific antigen; Alkaline phosphatase; Lactate dehydrogenase; Prognosis; Enzalutamide; bmCRPC
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-09483-7

In patients with bone metastatic castration-resistant prostate cancer (bmCRPC) on systemic treatment, it is difficult to differentiate between continuous rise of prostate specific antigen (PSA) representing progression, and PSA-surge, which is followed by clinical response or stable disease. The purpose of this study was to evaluate the prognostic value of dynamic changes of alkaline phosphatase (ALP) and lactic acid dehydrogenase (LDH) levels as a predictor of clinical efficacy or therapeutic resistance of patients who do not show a sufficient initial PSA decline of ≥50% from baseline during early therapy with Enzalutamide. Forty-eight men with bmCRPC on Enzalutamide 07/2010-09/2019 with initially rising PSA were analyzed. We monitored PSA, LDH and ALP at week 0, 2, 4, and every 4 weeks thereafter and analyzed the correlation between ALP rising at 12 weeks with or without LDH-normalization and the association with survival. For this we used Kaplan Meier analysis and uni- and multivariate cox-regression models. In Kaplan-Meier analysis, ALP rising at 12 weeks with or without LDH-normalization was associated with significantly worse median progression-free survival (PFS) of 3 months vs. 5 months (Log rank P = 0.02) and 3 months vs. 5 months (P = 0.01), respectively and overall survival (OS) with 8 months vs. 15 months (P = 0.02) and 8 months vs. 17 months (P < 0.01). In univariate analysis of PFS, ALP rising at 12 weeks alone, ALP rising at 12 weeks without LDH-normalization and application of Enzalutamide after chemotherapy showed a statistically significant association towards shorter PFS (hazard ratio (HR): 0.51, P = 0.04; HR: 0.48, P = 0.03; HR: 0.48, P = 0.03). Worse OS was significantly associated with ALP rising at 12 weeks alone, ALP rising at 12 weeks without LDH-normalization, and application of Enzalutamide after chemotherapy (HR: 0.47, P = 0.02; HR: 0.36, P < 0.01; HR: 0.31, P < 0.01). In multivariate analysis only the application of Enzalutamide after chemotherapy remained an independent prognostic factor for worse OS (HR: 0.36, P = 0.01). Dynamic changes of ALP (non-rise) and LDH (normalization) under therapy with Enzalutamide may be associated with clinical benefit, better PFS, and OS in patients with bmCRPC who do not show a PSA decline.